Полимиозит/дерматомиозит: дифференциальная диагностика
https://doi.org/10.14412/1995-4484-2016-191-198
Аннотация
В лекции рассматривается проблема редких системных заболеваний соединительной ткани – идиопатических воспалительных миопатий (ИВМ). Подчеркивается клинико-иммунологическая неоднородность их подтипов, определяющая терапевтическую тактику и прогноз. Представлены диагностические критерии ИВМ. Предлагается алгоритм дифференциальной диагностики, который базируется на исключении фенотипически сходных форм миопатий различного генеза.
Об авторе
О. А. АнтелаваРоссия
Институт профессионального образования
кафедра ревматологии
канд. мед. наук
Список литературы
1. Plotz PH, Dalakas M, Leff RL, et al. Current concepts in the idiopathic inflammatory myopathies: Polymyositis, dermatomyositis and related disorders. Ann Intern Med. 1989;111:143. doi: 10.7326/0003-4819-111-2-143
2. Dalakas M. Mechanisms of disease:signaling pathways and immunobyology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006;2(4):219-27. doi: 10.1038/ncprheum0140
3. Sarkar K, Miller FW. Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies. Autoimmunity. 2004 Jun;37(4):291-4. doi: 10.1080/08916930410001710839
4. Gazeley DJ, Cronin ME. Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskel Dis. 2011;3:315-24. doi: 10.1177/1759720X11415306
5. Mastaglia FL. Inflammatory muscle diseases. Neurol India. 2008;56:263-70. doi: 10.4103/0028-3886.43444
6. Van der Kooi AJ, de Visser M. Idiopathic inflammatory myopathies. Handb Clin Neurol. 2014;119:495-512. doi: 10.1016/B978-0-7020-4086-3.00032-1
7. Раденска-Лоповок СГ. Основные разновидности воспалительных миопатий: морфологическая дифференциальная диагностика. Нервно-мышечные болезни. 2011;(1):5-8 [Radenska-Lopovok SG. The main varieties of inflammatory myopathies: morphological differential diagnosis. Nervno-Myshechnye Bolezni. 2011;(1):5-8 (In Russ.)].
8. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with upregulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17:194-200. doi: 10.1016/j.nmd.2006.10.007
9. Lunberg I, Ulfgren A-K, Nyberg P, et al. Cynokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40:865-74. doi: 10.1002/art.1780400514
10. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg. 2009;Psychiat 80:1186-93.
11. Насонов ЕЛ, Штутман ВЗ, Саложин КВ и др. Клинико-иммунологическая гетерогенность идиопатических воспалительных миопатий. Клиническая медицина. 1995;(2):3-8 [Nasonov EL, Shtutman VZ, Salozhin KV, et al. Clinical and immunological heterogeneity of idiopathic inflammatory myopathies. Klinicheskaya Meditsina. 1995;(2):3-8 (In Russ.)].
12. Lega JC, Cottin V, Fabien N, et al. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol. 2010;37(5):1000-9. doi: 10.3899/jrheum.090652
13. Ghirardello A, Zampieri S, Tarricone E, et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity. 2006;39:217-21. doi: 10.1080/08916930600622645
14. Ghirardello A, Zampieri S, Iaccarino L, et al. Anti-MI-2 antibodies. Autoimmunity. 2005;38:79-83 doi: 10.1080/08916930400022681
15. Zampieri S, Ghirardello A, Iaccarino L, et al. Anti-JO-1 antibodies. Autoimmunity. 2005;38:73-8. doi: 10.1080/08916930400022640
16. Mahler M, Raijmakers R, Dä hnrich C, et al. Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. Arthritis Res Ther. 2005;7(3):R704-13. doi: 10.1186/ar1729
17. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis) Presentation of six new cases and review of the literature. J Am Acad Dermatol. 1991;24:959-66. doi: 10.1016/0190-9622(91)70153-S
18. Sontheimer RD. A portable digital microphotography unit for rapid documentation of periungualnailfold capillary changes in autoimmune connective tissue diseases. J Rheumatol. 2004 Mar;31(3):539-44.
19. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung diseasewith anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012 May 15.
20. Ghazi E, Sontheimer RD, Werth VP. The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. Clin Exp Rheumatol. 2013 Jan-Feb;31(1):128- 34. Epub 2012 Nov 22.
21. Антелава ОА. Паранеопластический миозит. Особенности дебюта, клинической картины, течения, стероид-респонсивности. Научно-практическая ревматология. 2013;51(2):181-5 [Antelava OA. The specific features of the onset, clinical picture, steroid responsiveness of paraneoplastic myositis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):181-5 (In Russ.)]. doi: 10.14412/1995-4484-2013-647
22. Christopher-Stine L, Casciola-Rosen LA, Hong,G, et al. A novel autoantibody recognizing 200-kd and100 kd proteins is associated with an immune mediated ecrotizing myopathy. Arthritis Rheum. 2010;62:2757-66. doi: 10.1002/art.27572
23. So MW, Koo BS, Kim YGC, et al. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and olymyositis. J Rheumatol. 2011;38(11):2432-5. doi: 10.3899/jrheum.110320
24. Антелава ОА, Тарасова ГМ, Сажина ЕГ и др. Антисинтетазный синдром — наиболее тяжелый подтип полимиозита/дерматомиозита (описание случаев). Современная ревматология. 2009;3(4):54-8 [Antelava OA, Tarasova GM, Sazhina EG, et al. Antisynthetase syndrome is the most severe subtype of polymyositis/dermatomyositis: description of cases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2009;3(4):54-8 (In Russ.)]. doi: 10.14412/1996-7012-2009-574
25. Ананьева ЛП, Волков АВ, Смирнов АВ, Антелава ОА. Поражение органов дыхания при системных заболеваниях соеди- нительной ткани. В кн.: Чучалин АГ, редактор. Респираторная медицина: Руководство. Москва: ГЭОТАР-Медиа; 2007. Т. 2. С. 251-68 [Anan’eva LP, Volkov AV, Smirnov AV, Antelava OA. The defeat of the respiratory system in systemic diseases of connective tissue. In: Chuchalin AG, editor. Respiratornaya meditsina: Rukovodstvo [Respiratory Medicine: A Guide]. Moscow: GEOTAR-Media; 2007. Vol. 2. P. 251-68].
26. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol. 2010;22:633-8. doi: 10.1097/BOR.0b013e32833f1970
27. Антелава ОА, Балабанова РМ, Сажина ЕГ и др. Особенности дебюта и течения антисинтетазного синдрома как наиболее тяжелого подтипа полимиозита/дерматомиозита. Русский медицинский журнал. 2009;21:1443 [Antelava OA, Balabanova RM, Sazhina EG, et al. Features debut and course antisintetaznogo syndrome as the most severe subtype of polymyositis/dermatomyositis. Russkii Meditsinskii Zhurnal. 2009;21:1443 (In Russ.)].
28. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome.Curr Rheumatol Rep. 2011;13:175-81. doi: 10.1007/s11926- 011-0176-8
29. Антелава ОА, Бондаренко ИБ, Хитров АН, Насонов ЕЛ. Поражение дыхательной системы при полимиозите/дерматоми- озите. Русский медицинский журнал. 2008;34(24):1633-7 [Antelava OA, Bondarenko IB, Khitrov AN, Nasonov EL. The defeat of the respiratory system with polymyositis/dermatomyositis. Russkii Meditsinskii Zhurnal. 2008;34(24):1633-7 (In Russ.)].
30. Mileti LM, Strek ME, Niewold TB, et al. Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol. 2009;15(5):254-5. doi: 10.1097/RHU.0b013e3181b0e910
31. Hervier B, Wallaert B, Hachulla E, et al. Clinical manifestations of antisynthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology (Oxford). 2010;49(5):972-6. doi: 10.1093/rheumatology/kep455
32. Handa T, Nagai S, Kawabata D, et al. Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med. 2005;44(4):319-25. doi: 10.2169/internalmedicine.44.319
33. Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of antiPL-12 autoantibody: cohort study and review of the literature. Chest. 2009;135(6):1550-6. doi: 10.1378/chest.08-2233
34. Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007;34(5):1012-8.
35. Arnett FC, Targoff IN, Mimori T, et al. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996;39:1507-18. doi: 10.1002/art.1780390910
36. Hengstman GJD, Brouwer R, Vree Egberts WTM, et al. Clinical and serological characteristics of 125 Dutch myositis patients; myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol. 2002;249:69- 75. doi: 10.1007/PL00007850
37. Hirakata M, Nakamura K, Fuji J, et al. Clinical and immunogenetic features of anti-SRP autoantibodies in Japanese patients. Arthritis Rheum. 1995;38:S321.
38. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle. Arthritis Rheum. 1990;33:1361-70. doi: 10.1002/art.1780330908
39. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996;40(4):581-6. doi: 10.1002/ana.410400407
40. Barohn RJ, Amato AA. Inclusion body myositis. Curr Treat Options Neurol. 2000;2(1):7-12. doi: 10.1007/s11940-000-0019-9
41. Phillips BA, Cala LA, Thickbroom GW, et al. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle Nerve. 2001;24:1526-34. doi: 10.1002/mus.1178
42. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry. 2008;79(9):1056-60. doi: 10.1136/jnnp.2007.138891
43. Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995;45(7):1302-4. doi: 10.1212/WNL.45.7.1302
44. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112(Pt 3):727-47. doi: 10.1093/brain/112.3.727
45. Rodriguez Cruz PM, Needham M, Hollingsworth P, et al. Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis. Neuromuscul Disord. 2014;24:1036-41. doi: 10.1016/j.nmd.2014.08.003
46. Della Marca G, Sancricca C, Losurdo A, et al. Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis. Clin Neurophysiol. 2013;124:1615-21. doi: 10.1016/j.clinph.2013.03.002
47. Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167-75. doi: 10.1093/brain/awr217
48. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403-7. doi: 10.1056/NEJM197502202920807
49. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-7. doi: 10.1056/NEJM197502132920706
50. Targoff IN, Miller FW, Medsger TA, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9:527-35. doi: 10.1097/00002281-199711000-00008
51. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004 May;14(5):337-45. doi: 10.1016/j.nmd.2004.02.006
52. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705-13. doi: 10.1002/ana.410380504
53. Selva-O’Callaghan A, Fonollosa-Pla V, Trallero-Araguas E, et al. Nailfold capillary microscopy in adults withinflammatory myopathy. Sem Arthritis Rheum. 2010a;39:398-404. doi: 10.1016/j.semarthrit.2008.09.003
54. Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63(1):53-9. doi: 10.1136/thx.2006.069237
55. Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and otherproximalmyopathies. Thorax. 1983;38(8):616-23. doi: 10.1136/thx.38.8.616
56. Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford). 2006;45 Suppl 4: iv18-21. doi: 10.1093/rheumatology/kel311
57. Costa AF, Di Primio GA, Schweitzer ME. Magnetic resonance imaging of muscle disease: A pattern-based approach. Muscle Nerve. 2012;46:465-81. doi: 10.1002/mus.23370
58. Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford). 2011;50:1153-61. doi: 10.1093/rheumatology/ker001
59. Tasca G, Monforte M, De Fino C, et al. MRI pattern recognition in sporadic inclusion body myositis. Muscle Nerve. 2015;52(6):956-62. doi: 10.1002/mus.24661
60. Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol. 2002;29:1897-906.
61. Антелава ОА, Насонов ЕЛ. Современные методы оценки активности и повреждения при идиопатических воспалительных миопатиях. Научно-практическая ревматология. 2007;45(1):59-62 [Antelava OA, Nasonov EL. Modern methods of evaluation activity and damage in idiopathic inflammatory myopathies. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2007;45(1):59-62 (In Russ.)].
Рецензия
Для цитирования:
Антелава О.А. Полимиозит/дерматомиозит: дифференциальная диагностика. Научно-практическая ревматология. 2016;54(2):191-198. https://doi.org/10.14412/1995-4484-2016-191-198
For citation:
Antelava O.A. POLYMYOSITIS/DERMATOMIOSITIS: DIFFERENTIAL DIAGNOSIS. Rheumatology Science and Practice. 2016;54(2):191-198. (In Russ.) https://doi.org/10.14412/1995-4484-2016-191-198